



Docket No.: PF381C1D1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ni et al.

Application No.: 10/713,208

Confirmation No.: 5854

Filed: November 17, 2003

Art Unit: 1644

For: I-FLICE, A Novel Inhibitor of Tumor Necrosis  
Factor Receptor-1 and CD 95 Induced  
Apoptosis

Examiner: P. N. Huynh

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-IP listed on the attached Form PTO/SB/08. A copy of reference AA is enclosed.

Copies of references AB-AI, ED-II, and IK-IP were submitted by Applicants in connection with U. S. Patent Application Serial No. 09/489,155, filed January 21, 2000, to which the instant application claims priority under 35 U.S.C. § 120. Copies of references AJ-EC and IJ were submitted by Applicants or cited by the Examiner in related U. S. Patent Application Serial No. 09/009,893, filed January 21, 1998. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of references AB-IP.

12/21/2004 SMINASS1 00000124 083425 10713208

01 FC:1806 180.00 DA

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:5 and the corresponding cDNA clone of this application are related to SEQ ID NOs:164706, 215903, and 219749 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of those portions of U.S. Patent Application Serial No. 09/912,293, which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee(s).

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.


Please charge our Deposit Account No. 08-3425 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith, or with any paper hereafter filed in this application by Applicants to our Deposit Account No. 08-3425, under Attorney Docket No. PF381C1D1.

Dated: Dec 20, 2004

Respectfully submitted,

By   
Melissa J. Pytel

Registration No.: 41,512  
HUMAN GENOME SCIENCES, INC.  
Intellectual Property Dept.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 610-5764



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	1	of	14	Attorney Docket Number	PF381C1D1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	09/912,293		Rosen et al.	Not Published	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 164706, 215903, and 219749

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AB	WO	94/04686		Biogen, Inc.			
	AC	WO	96/05306	A2	Unknown	02-22-1996		
	AD	WO	97/32996	A1	Institut National De La Sante Et De La Recherche Medicale (INSERM)	09-12-1997		
	AE	WO	98/33883	A1	Tularik Inc.	08-06-1998		
	AF	WO	98/44104	A2	Apoxis SA	10-08-1998		
	AG	WO	98/52963	A1	Thomas Jefferson Univ.	11-26-1998		
	AH	CA	2,285,669		Apotech Res. & Dev. Ltd.	10-08-1998		
	AI	EP	0 816 499	A2	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	01-07-1998		
	AJ	EP	0 841 399	A2	SmithKline Beecham Corporation	05-13-1998		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AK	Adams, M.D. <i>et al.</i> , "Complementary DNA sequencing: expressed sequence tags and human genome project," <i>Science</i> 252:1651-1656 (1991).	

Examiner Signature	Date Considered
-----------------------	--------------------

<sup>1</sup> Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	2	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	AL	Adams, M.D. <i>et al.</i> , "Sequence identification of 2,375 human brain genes," <i>Nature</i> 355:632-634 (1992).			
	AM	Adams, M.D. <i>et al.</i> , "Rapid cDNA sequence (expressed sequence tags) from a directionally cloned human infant brain cDNA library," <i>Nature genetics</i> 4:373-380 (1993).			
	AN	Adams, M.D. <i>et al.</i> , "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence," <i>Nature</i> 377:3-174 (1995).			
	AO	Alnemri, E.S. <i>et al.</i> , "Human ICE/CED-3 protease nomenclature," <i>Cell</i> 87:171 (October 1996).			
	AP	Bertin, J. <i>et al.</i> , "Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis," <i>Proc. Natl. Sci. Acad. USA</i> 94:1172-1176 (February 1997).			
	AQ	Boldin, M.P. <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF Receptor-induced cell death," <i>Cell</i> 85:803-815 (June 1996).			
	AR	Chinnaiyan, A.M. <i>et al.</i> , "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis," <i>Cell</i> 81:505-512 (1995).			
	AS	Chinnaiyan, A.M. <i>et al.</i> , "FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor-receptor-induced apoptosis," <i>J. Biol. Chem.</i> 271(9):4961-4965 (March 1996).			
	AT	Chinnaiyan, A.M. and V.M. Dixit, "The cell-death machine," <i>Curr. Biol.</i> 6:55-562 (May 1996).			
	AU	Fernandes-Alnemri, T. <i>et al.</i> , "In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains," <i>Proc. Natl. Acad. Sci. USA</i> 93:7464-7469 (July 1996).			
	AV	Fraser, A. and G. Evan, "A license to kill," <i>Cell</i> 85:781-784 (June 1996).			
	AW	Henkart, P.A., "ICE family proteases: mediators of all apoptotic cell death?," <i>Immunity</i> 4:195-201 (March 1996).			
	AX	Hu, S. <i>et al.</i> , "A novel family of viral death effector domain-containing molecules that inhibit both CD-95 and tumor necrosis factor receptor-1-induced apoptosis," <i>J. Biol. Chem.</i> 272(15):9621-9624 (April 1997).			
	AY	Hu, S. <i>et al.</i> , "I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis," <i>J. Biol. Chem.</i> 272(28):17255-17257 (July 1997).			
	AZ	Irlmer, M. <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> 388:190-195 (July 1997).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	3	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	BA	Muzio, M. <i>et al.</i> , "FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex," <i>Cell</i> 85:817-827 (June 1996).			
	BB	Muzio, M. <i>et al.</i> , "FLICE induced apoptosis in a cell-free system," <i>J. Biol. Chem.</i> 272(5):2952-2956 (January 1997).			
	BC	O'Rourke, K.M. <i>et al.</i> , "Thrombospondin 1 and Thrombospondin 2 are expressed as both homo- and heterotrimers," <i>J. Biol. Chem.</i> 267(35):24921-24924 (1992).			
	BD	Rotonda, J. <i>et al.</i> , "The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis," <i>Nature Structural Biology</i> 3(7):619-625 (July 1996).			
	BE	Shen, Y. and T.E. Shen, "Viruses and apoptosis," <i>Curr. Biol.</i> 5:105-111 (1995).			
	BF	Shu, H.-B. <i>et al.</i> , "Casper is a FADD- and caspase-related inducer of apoptosis," <i>Immunity</i> 6:751-763 (June 1997).			
	BG	Srinivasula, S.M. <i>et al.</i> , "Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases," <i>Proc. Natl. Acad. Sci. USA</i> 93:14486-14491 (December 1996).			
	BH	Thome, M. <i>et al.</i> , "Viral FLICE-inhibitory protein (FLIPs) prevent apoptosis induced by death receptors," <i>Nature</i> 386:517-521 (April 1997).			
	BI	Vincenz, C. and V.M. Dixit, "Fas-associated death domain protein interleukin 1 $\beta$ -converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximately involved in CD95- and p55-mediated death signaling," <i>J. Biol. Chem.</i> 272(10):6578-6583 (March 1997).			
	BJ	Walker, N.P.C. <i>et al.</i> , "Crystal structure of the cysteine protease interleukin 1 $\beta$ -converting enzyme: a (p20/p10) <sub>2</sub> homodimer," <i>Cell</i> 78:343-352 (1994).			
	BK	Wilson, K.P. <i>et al.</i> , "Structure and mechanism of interleukin 1 $\beta$ -converting enzyme," <i>Nature</i> 370:270-275 (1994).			
	BL	NCBI Entrez, Genbank Report, Accession No. T05118, from Adams, M.D. <i>et al.</i> (1993), with revision history.			
	BM	NCBI Entrez, Genbank Report, Accession No. Z42895, from Auffray, C. <i>et al.</i> (1994), with revision history.			
	BN	NCBI Entrez, Genbank Report, Accession No. T48754, from Hillier, L. <i>et al.</i> (1995), with revision history.			
	BO	NCBI Entrez, Genbank Report, Accession No. F13176, from Auffray, C. <i>et al.</i> (1995), with revision history.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	4	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	BP	NCBI Entrez, Genbank Report, Accession No. T93307, from Hillier, L. <i>et al.</i> (1995), with revision history.			
	BQ	NCBI Entrez, Genbank Report, Accession No. H15978, from Hillier, L. <i>et al.</i> (1995), with revision history.			
	BR	NCBI Entrez, Genbank Report, Accession No. H15052, from Hillier, L. <i>et al.</i> (1995), with revision history.			
	BS	NCBI Entrez, Genbank Report, Accession No. T30922, from Adams, M.D. <i>et al.</i> (1995), with revision history.			
	BT	NCBI Entrez, Genbank Report, Accession No. T30864, from Adams, M.D. <i>et al.</i> (1995), with revision history.			
	BU	NCBI Entrez, Genbank Report, Accession No. H68343, from Hillier, L. <i>et al.</i> (1995), with revision history.			
	BV	NCBI Entrez, Genbank Report, Accession No. D83882, from Takeda, J. (April 1996), with revision history.			
	BW	NCBI Entrez, Genbank Report, Accession No. W52946, from Hillier, L. <i>et al.</i> (May 1996), with revision history.			
	BX	NCBI Entrez, Genbank Report, Accession No. W60406, from Hillier, L. <i>et al.</i> (June 1996), with revision history.			
	BY	NCBI Entrez, Genbank Report, Accession No. W23795, from Hillier, L. <i>et al.</i> (August 1996), with revision history.			
	BZ	NCBI Entrez, Genbank Report, Accession No. N94588, from Hillier, L. <i>et al.</i> (August 1996), with revision history.			
	CA	NCBI Entrez, Genbank Report, Accession No. C05795, from Takeda J. (October 1996), with revision history.			
	CB	NCBI Entrez, Genbank Report, Accession No. C05730, from Takeda J. (October 1996), with revision history.			
	CC	NCBI Entrez, Genbank Report, Accession No. AA135811, from Hillier, L. <i>et al.</i> (November 1996), with revision history.			
	CD	NCBI Entrez, Genbank Report, Accession No. AA149562, from Hillier, L. <i>et al.</i> (December 1996), with revision history.			
	CE	NCBI Entrez, Genbank Report, Accession No. AA151642, from Hillier, L. <i>et al.</i> (December 1996), with revision history.			
	CF	NCBI Entrez, Genbank Report, Accession No. AA198928, from Marra, M. <i>et al.</i> (February 1997), with revision history.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	5	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CG	NCBI Entrez, Genbank Report, Accession No. AA296309, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CH	NCBI Entrez, Genbank Report, Accession No. AA296229, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CI	NCBI Entrez, Genbank Report, Accession No. AA296174, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CJ	NCBI Entrez, Genbank Report, Accession No. AA302978, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CK	NCBI Entrez, Genbank Report, Accession No. AA302968, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CL	NCBI Entrez, Genbank Report, Accession No. AA358042, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CM	NCBI Entrez, Genbank Report, Accession No. AA358043, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CN	NCBI Entrez, Genbank Report, Accession No. AA379905, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CO	NCBI Entrez, Genbank Report, Accession No. AA364006, from Adams, M.D. <i>et al.</i> (April 1997), with revision history.			
	CP	NCBI Entrez, Genbank Report, Accession No. AA001257, from Hillier, L. <i>et al.</i> (May 1997), with revision history.			
	CQ	NCBI Entrez, Genbank Report, Accession No. AA002262, from Hillier, L. <i>et al.</i> (May 1997), with revision history.			
	CR	NCBI Entrez, Genbank Report, Accession No. AA115793, from Hillier, L. <i>et al.</i> (May 1997), with revision history.			
	CS	NCBI Entrez, Genbank Report, Accession No. AA115792, from Hillier, L. <i>et al.</i> (May 1997), with revision history.			
	CT	NCBI Entrez, Genbank Report, Accession No. AA453766, from Hillier, L. <i>et al.</i> (June 1997), with revision history.			
	CU	NCBI Entrez, Genbank Report, Accession No. AA453850, from Hillier, L. <i>et al.</i> (June 1997), with revision history.			
	CV	NCBI Entrez, Genbank Report, Accession No. AA501289, from Marra, M. <i>et al.</i> (July 1997), with revision history.			
	CW	NCBI Entrez, Genbank Report, Accession No. U97075, from Irlmer, M. <i>et al.</i> (July 1997), with revision history.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	6	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CX	NCBI Entrez, Genbank Report, Accession No. U97076, from Irlmer, M. <i>et al.</i> (July 1997), with revision history.			
	CY	NCBI Entrez, Genbank Report, Accession No. U97074, from Irlmer, M. <i>et al.</i> (July 1997), with revision history.			
	CZ	NCBI Entrez, Genbank Report, Accession No. AF010127, from Shu, H.B. <i>et al.</i> (July 1997), with revision history.			
	DA	NCBI Entrez, Genbank Report, Accession No. AF005775, from Inohara, N. <i>et al.</i> (July 1997), with revision history.			
	DB	NCBI Entrez, Genbank Report, Accession No. AF005774, from Inohara, N. <i>et al.</i> (July 1997), with revision history.			
	DC	NCBI Entrez, Genbank Report, Accession No. AA526099, from NCI-CGAP (August 1997), with revision history.			
	DD	NCBI Entrez, Genbank Report, Accession No. AA467995, from NCI-CGAP (August 1997), with revision history.			
	DE	NCBI Entrez, Genbank Report, Accession No. AA468056, from NCI-CGAP (August 1997), with revision history.			
	DF	NCBI Entrez, Genbank Report, Accession No. AA467756, from NCI-CGAP (August 1997), with revision history.			
	DG	NCBI Entrez, Genbank Report, Accession No. AA467938, from NCI-CGAP (August 1997), with revision history.			
	DH	NCBI Entrez, Genbank Report, Accession No. AA229005, from NCI-CGAP (August 1997), with revision history.			
	DI	NCBI Entrez, Genbank Report, Accession No. AA565691, from NCI-CGAP (September 1997), with revision history.			
	DJ	NCBI Entrez, Genbank Report, Accession No. AA558404, from NCI-CGAP (September 1997), with revision history.			
	DK	NCBI Entrez, Genbank Report, Accession No. AA525331, from NCI-CGAP (September 1997), with revision history.			
	DL	NCBI Entrez, Genbank Report, Accession No. AF00619, from Srinivasula, S.M. <i>et al.</i> (September 1997), with revision history.			
	DM	NCBI Entrez, Genbank Report, Accession No. AF009618, from Srinivasula, S.M. <i>et al.</i> (September 1997), with revision history.			
	DN	NCBI Entrez, Genbank Report, Accession No. AF009616, from Srinivasula, S.M. <i>et al.</i> (September 1997), with revision history.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	7	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	DO	NCBI Entrez, Genbank Report, Accession No. AF009617, from Srinivasula, S.M. <i>et al.</i> (September 1997), with revision history.			
	DP	NCBI Entrez, Genbank Report, Accession No. AA663074, from Hillier, L. <i>et al.</i> (November 1997), with revision history.			
	DQ	NCBI Entrez, Genbank Report, Accession No. AA613966, from NCI-CGAP (October 1997), with revision history.			
	DR	NCBI Entrez, Genbank Report, Accession No. AA610255, from NCI-CGAP (December 1997), with revision history.			
	DS	NCBI Entrez, Genbank Report, Accession No. AA70614, from Hillier, L. <i>et al.</i> (December 1997), with revision history.			
	DT	NCBI Entrez, Genbank Report, Accession No. Z80780, from Albig, W. <i>et al.</i> (September 2, 1996).			
	DU	NCBI Entrez, Genbank Report, Accession No. AF009619, from Srinivasula, S.M. <i>et al.</i> (September 23, 1997).			
	DV	NCBI Entrez, Genbank Report, Accession No. U85059, from Han, D.K.M. <i>et al.</i> (November 4, 1997).			
	DW	NCBI Entrez, Genbank Report, Accession No. Y14039, from Goltsev, Y.V. <i>et al.</i> (November 30, 1997).			
	DX	NCBI Entrez, Genbank Report, Accession No. Y14040, from Goltsev, Y.V. <i>et al.</i> (November 30, 1997).			
	DY	NCBI Entrez, Genbank Report, Accession No. Y14041, from Goltsev, Y.V. <i>et al.</i> (November 30, 1997).			
	DZ	NCBI Entrez, Genbank Report, Accession No. Y14042, from Goltsev, Y.V. <i>et al.</i> (November 30, 1997).			
	EA	NCBI Entrez, Genbank Report, Accession No. AF015451, from Rasper, D.M. <i>et al.</i> (May 16, 1998).			
	EB	NCBI Entrez, Genbank Report, Accession No. AF015452, from Rasper, D.M. <i>et al.</i> (May 16, 1998).			
	EC	NCBI Entrez, Genbank Report, Accession No. Z85996, from Palmer, S. (June 18, 1998).			
	ED	NCBI Entrez, Genbank Report, Accession No. Z15027, from Bougueleret, L. (June 25, 1997).			
	EE	NCBI Entrez, Genbank Report, Accession No. M34133, from Woese, C.R. (April 27, 1993).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	8	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	EF	NCBI Entrez, Genbank Report, Accession No. M80463, from Hu, Y. <i>et al.</i> (March 4, 1994).			
	EG	NCBI Entrez, Genbank Report, Accession No. X80877, from Kelly, M.M. <i>et al.</i> (April 2, 1998).			
	EH	NCBI Entrez, Genbank Report, Accession No. U22416, from Chen, H. <i>et al.</i> (July 26, 1996).			
	EI	NCBI Entrez, Genbank Report, Accession No. U16720, from Sanjanwala, B. <i>et al.</i> (October 28, 1995).			
	EJ	NCBI Entrez, Genbank Report, Accession No. U22427, from Bennasar, A. <i>et al.</i> (March 26, 1996).			
	EK	NCBI Entrez, Genbank Report, Accession No. U25280, from Bennasar, A. <i>et al.</i> (March 26, 1996).			
	EL	NCBI Entrez, Genbank Report, Accession No. U26415, from Bennasar, A. <i>et al.</i> (April 4, 1996).			
	EM	NCBI Entrez, Genbank Report, Accession No. Z68873, from Odell, C. (November 23, 1999).			
	EN	NCBI Entrez, Genbank Report, Accession No. S79859, from Barnier, J.V. <i>et al.</i> (February 11, 1996).			
	EO	NCBI Entrez, Genbank Report, Accession No. U58659, from Frischer, M.E. <i>et al.</i> (June 19, 1996).			
	EP	NCBI Entrez, Genbank Report, Accession No. D90605, from Matsuoka, Y. (February 7, 1996).			
	EQ	NCBI Entrez, Genbank Report, Accession No. D90634, from Matsuoka, Y. (February 7, 1996).			
	ER	NCBI Entrez, Genbank Report, Accession No. U67563, from Bult, C.J. <i>et al.</i> (January 28, 1998).			
	ES	NCBI Entrez, Genbank Report, Accession No. U64001, from Pinhassi, J. <i>et al.</i> (September 13, 1999).			
	ET	NCBI Entrez, Genbank Report, Accession No. Z80780, from Albig, W. <i>et al.</i> (September 27, 1996).			
	EU	NCBI Entrez, Genbank Report, Accession No. Z85996, from Tripodis, N. <i>et al.</i> (November 23, 1999).			
	EV	NCBI Entrez, Genbank Report, Accession No. Z76668, from Moore, E.R.B. <i>et al.</i> (March 25, 1997).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	9	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	EW	NCBI Entrez, Genbank Report, Accession No. U70698, from Rappe, M.S. <i>et al.</i> (December 21, 1997).	
	EX	NCBI Entrez, Genbank Report, Accession No. AF038653, from Metcalf, W.W. <i>et al.</i> (November 5, 1998).	
	EY	NCBI Entrez, Genbank Report, Accession No. F05214, from Auffray, C. <i>et al.</i> (month "first seen at NCBI" February 1995), with sequence revision history and disclaimer.	
	EZ	NCBI Entrez, Genbank Report, Accession No. P39188, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FA	NCBI Entrez, Genbank Report, Accession No. P39189, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FB	NCBI Entrez, Genbank Report, Accession No. P39190, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FC	NCBI Entrez, Genbank Report, Accession No. P39191, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FD	NCBI Entrez, Genbank Report, Accession No. P39192, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FE	NCBI Entrez, Genbank Report, Accession No. P39193, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FF	NCBI Entrez, Genbank Report, Accession No. P39194, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FG	NCBI Entrez, Genbank Report, Accession No. P39195, from Claverie, J.M. <i>et al.</i> (month "first seen at NCBI" March 1995), with sequence revision history and disclaimer.	
	FH	NCBI Entrez, Genbank Report, Accession No. R16389, from Hillier, L. <i>et al.</i> (month "first seen at NCBI" April 1995), with sequence revision history and disclaimer.	
	FI	NCBI Entrez, Genbank Report, Accession No. Z68273, from Mungall, A. (month "first seen at NCBI" December 1995), with sequence revision history and disclaimer.	
	FJ	NCBI Entrez, Genbank Report, Accession No. AAC50602, from Munzio, M. <i>et al.</i> (month "first seen at NCBI" June 1996), with sequence revision history and disclaimer.	
	FK	NCBI Entrez, Genbank Report, Accession No. CAA66854, from Boldin, M.P. <i>et al.</i> (month "first seen at NCBI" July 1996), with sequence revision history and disclaimer.	
	FL	NCBI Entrez, Genbank Report, Accession No. AAC50645, from Fernandes-Alnemri, T.F. <i>et al.</i> (month "first seen at NCBI" July 1996), with sequence revision history and disclaimer.	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	10	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	FM	NCBI Entrez, Genbank Report, Accession No. CAA66853, Boldin, M.P. <i>et al.</i> (month "first seen at NCBI" July 1996), with sequence revision history and disclaimer.			
	FN	NCBI Entrez, Genbank Report, Accession No. CAA66855, from Boldin, M.P. <i>et al.</i> (month "first seen at NCBI" July 1996), with sequence revision history and disclaimer.			
	FO	NCBI Entrez, Genbank Report, Accession No. AAC50644, from Fernandes-Alnemri, T.F. <i>et al.</i> (month "first seen at NCBI" August 1996), with sequence revision history and disclaimer.			
	FP	NCBI Entrez, Genbank Report, Accession No. AAC29881, from Johnson, A.L. <i>et al.</i> (month "first seen at NCBI" August 1996), with sequence revision history and disclaimer.			
	FQ	NCBI Entrez, Genbank Report, Accession No. Z83844, from Pearce, A. (month "first seen at NCBI" January 1997), with sequence revision history and disclaimer.			
	FR	NCBI Entrez, Genbank Report, Accession No. AAB46730, Vincenz, C. and Dixit, V.M. (month "first seen at NCBI" February 1997), with sequence revision history and disclaimer.			
	FS	NCBI Entrez, Genbank Report, Accession No. AAB49034, Westin, E.H. and Gorse, K.M. (month "first seen at NCBI" March 1997), with sequence revision history and disclaimer.			
	FT	NCBI Entrez, Genbank Report, Accession No. AA295653, Adams, M.D. <i>et al.</i> (month "first seen at NCBI" April 1997), with sequence revision history and disclaimer.			
	FU	NCBI Entrez, Genbank Report, Accession No. AA358043, Adams, M.D. <i>et al.</i> (month "first seen at NCBI" April 1997), with sequence revision history and disclaimer.			
	FV	NCBI Entrez, Genbank Report, Accession No. AA384922, Adams, M.D. <i>et al.</i> (month "first seen at NCBI" April 1997), with sequence revision history and disclaimer.			
	FW	NCBI Entrez, Genbank Report, Accession No. JC5238, from Sosa, M.A. <i>et al.</i> (create date: April 1997).			
	FX	NCBI Entrez, Genbank Report, Accession No. Z93930, from Clark, G. <i>et al.</i> (month "first seen at NCBI" April 1997), with sequence revision history and disclaimer.			
	FY	NCBI Entrez, Genbank Report, Accession No. AAC53281, Irmeler, M. <i>et al.</i> (month "first seen at NCBI" July 1997), with sequence revision history and disclaimer.			
	FZ	NCBI Entrez, Genbank Report, Accession No. AAC15825, from Inohara, N. <i>et al.</i> (month "first seen at NCBI" July 1997), with sequence revision history and disclaimer.			
	GA	NCBI Entrez, Genbank Report, Accession No. AAC15826, from Inohara, N. <i>et al.</i> (month "first seen at NCBI" July 1997), with sequence revision history and disclaimer.			
	GB	NCBI Entrez, Genbank Report, Accession No. AC002476, from Graves, T. <i>et al.</i> (month "first seen at NCBI" August 1997), with sequence revision history and disclaimer.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	11	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	GC	NCBI Entrez, Genbank Report, Accession No. AAB70909, Srinivasula, S.M. <i>et al.</i> (month "first seen at NCBI" September 1997), with sequence revision history and disclaimer.			
	GD	NCBI Entrez, Genbank Report, Accession No. AAB70910, Srinivasula, S.M. <i>et al.</i> (month "first seen at NCBI" September 1997), with sequence revision history and disclaimer.			
	GE	NCBI Entrez, Genbank Report, Accession No. AAB70912, Srinivasula, S.M. <i>et al.</i> (month "first seen at NCBI" September 1997), with sequence revision history and disclaimer.			
	GF	NCBI Entrez, Genbank Report, Accession No. AAB70913, Srinivasula, S.M. <i>et al.</i> (month "first seen at NCBI" September 1997), with sequence revision history and disclaimer.			
	GG	NCBI Entrez, Genbank Report, Accession No. Z98941, from Kershaw, J. (month "first seen at NCBI" September 1997), with sequence revision history and disclaimer.			
	GH	NCBI Entrez, Genbank Report, Accession No. CAA04196, Kioschis, P. <i>et al.</i> (month "first seen at NCBI" October 1997), with sequence revision history and disclaimer.			
	GI	NCBI Entrez, Genbank Report, Accession No. B37964, Mahairas, G.G. <i>et al.</i> (month "first seen at NCBI" October 1997), with sequence revision history and disclaimer.			
	GJ	NCBI Entrez, Genbank Report, Accession No. B40201, Mahairas, G.G. <i>et al.</i> (month "first seen at NCBI" October 1997), with sequence revision history and disclaimer.			
	GK	NCBI Entrez, Genbank Report, Accession No. AAC51843, Lahn, B.T. and Page, D.C. (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GL	NCBI Entrez, Genbank Report, Accession No. CAA74366, Goltsev, Y.V. <i>et al.</i> (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GM	NCBI Entrez, Genbank Report, Accession No. CAA74367, Goltsev, Y.V. <i>et al.</i> (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GN	NCBI Entrez, Genbank Report, Accession No. CAA74368, Goltsev, Y.V. <i>et al.</i> (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GO	NCBI Entrez, Genbank Report, Accession No. CAA74369, Goltsev, Y.V. <i>et al.</i> (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GP	NCBI Entrez, Genbank Report, Accession No. AC003101, from Birren, B. <i>et al.</i> (month "first seen at NCBI" November 1997), with sequence revision history and disclaimer.			
	GQ	NCBI Entrez, Genbank Report, Accession No. AL009183, from Pearce, A. (month "first seen at NCBI" December 1997), with sequence revision history and disclaimer.			
	GR	NCBI Entrez, Genbank Report, Accession No. AC004060, from Stone, N.E. <i>et al.</i> (month "first seen at NCBI" January 1998), with sequence revision history and disclaimer.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	12	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	GS	NCBI Entrez, Genbank Report, Accession No. AAB99792, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GT	NCBI Entrez, Genbank Report, Accession No. AAB99793, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GU	NCBI Entrez, Genbank Report, Accession No. AAB99794, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GV	NCBI Entrez, Genbank Report, Accession No. AF041458, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GW	NCBI Entrez, Genbank Report, Accession No. AF041459, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GX	NCBI Entrez, Genbank Report, Accession No. AF041460, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GY	NCBI Entrez, Genbank Report, Accession No. AF041461, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	GZ	NCBI Entrez, Genbank Report, Accession No. AF041462, Hu, S. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	HA	NCBI Entrez, Genbank Report, Accession No. AC004099, from Birren, B. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	HB	NCBI Entrez, Genbank Report, Accession No. AC004106, from Muzny, D. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	HC	NCBI Entrez, Genbank Report, Accession No. AC004216, from Muzny, D. <i>et al.</i> (month "first seen at NCBI" February 1998), with sequence revision history and disclaimer.			
	HD	NCBI Entrez, Genbank Report, Accession No. AC004491, from Waterston, R. <i>et al.</i> (month "first seen at NCBI" March 1998), with sequence revision history and disclaimer.			
	HE	NCBI Entrez, Genbank Report, Accession No. AC004590, from Birren, B. <i>et al.</i> (month "first seen at NCBI" April 1998), with sequence revision history and disclaimer.			
	HF	NCBI Entrez, Genbank Report, Accession No. AAC16440, from Rasper, D.M. <i>et al.</i> (month "first seen at NCBI" May 1998), with sequence revision history and disclaimer.			
	HG	NCBI Entrez, Genbank Report, Accession No. AAC16441, from Rasper, D.M. <i>et al.</i> (month "first seen at NCBI" May 1998), with sequence revision history and disclaimer.			
	HH	NCBI Entrez, Genbank Report, Accession No. AF015450, from Rasper, D.M. <i>et al.</i> (month "first seen at NCBI" May 1998), with sequence revision history and disclaimer.			
	HI	NCBI Entrez, Genbank Report, Accession No. AI000325, from NCI-CGAP (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	13	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	HJ	NCBI Entrez, Genbank Report, Accession No. AC004821, from Waterston, R.H. <i>et al.</i> (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			
	HK	NCBI Entrez, Genbank Report, Accession No. AC005089, from Waterston, R.H. <i>et al.</i> (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			
	HL	NCBI Entrez, Genbank Report, Accession No. AC004834, from Waterston, R.H. <i>et al.</i> (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			
	HM	NCBI Entrez, Genbank Report, Accession No. AA922168, from NCI-CGAP (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			
	HN	NCBI Entrez, Genbank Report, Accession No. AAC40131, from Sakamaki, K. <i>et al.</i> (month "first seen at NCBI" June 1998), with sequence revision history and disclaimer.			
	HO	NCBI Entrez, Genbank Report, Accession No. AAC25713, from Rueda, B.R. <i>et al.</i> (month "first seen at NCBI" July 1998), with sequence revision history and disclaimer.			
	HP	NCBI Entrez, Genbank Report, Accession No. AAC32602, from Johnson, A.L. and Bridgham, J.T. (month "first seen at NCBI" August 1998), with sequence revision history and disclaimer.			
	HQ	NCBI Entrez, Genbank Report, Accession No. AL031302, from Griffiths, M. (month "first seen at NCBI" August 1998), with sequence revision history and disclaimer.			
	HR	NCBI Entrez, Genbank Report, Accession No. AC005529, from Ying, F. <i>et al.</i> (month "first seen at NCBI" August 1998), with sequence revision history and disclaimer.			
	HS	NCBI Entrez, Genbank Report, Accession No. AI139524, from NCI-CGAP (month "first seen at NCBI" September 1998), with sequence revision history and disclaimer.			
	HT	NCBI Entrez, Genbank Report, Accession No. AI041643, from NCI-CGAP (month "first seen at NCBI" September 1998), with sequence revision history and disclaimer.			
	HU	NCBI Entrez, Genbank Report, Accession No. AL031427, from Hall, R. (month "first seen at NCBI" September 1998), with sequence revision history and disclaimer.			
	HV	NCBI Entrez, Genbank Report, Accession No. AL031447, from Wray, P. (month "first seen at NCBI" September 1998), with sequence revision history and disclaimer.			
	HW	NCBI Entrez, Genbank Report, Accession No. AI094800, from NCI/NINDS-CGAP (month "first seen at NCBI" October 1998), with sequence revision history and disclaimer.			
	HX	NCBI Entrez, Genbank Report, Accession No. AI160682, from NCI-CGAP (month "first seen at NCBI" October 1998), with sequence revision history and disclaimer.			
	HY	NCBI Entrez, Genbank Report, Accession No. AC005803, from Birren, B. <i>et al.</i> (month "first seen at NCBI" October 1998), with sequence revision history and disclaimer.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>2</sup> Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/713,208
				Filing Date	November 17, 2003
				First Named Inventor	Ni et al.
				Group Art Unit	1644
				Examiner Name	Huynh, P.
Sheet	14	of	14	Attorney Docket Number	PF381C1D1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	HZ	NCBI Entrez, Genbank Report, Accession No. AC005952, from Lamerdin, J.E. <i>et al.</i> (month "first seen at NCBI" November 1998), with sequence revision history and disclaimer.			
	IA	NCBI Entrez, Genbank Report, Accession No. AI274957, from NCI-CGAP (month "first seen at NCBI" November 1998), with sequence revision history and disclaimer.			
	IB	NCBI Entrez, Genbank Report, Accession No. AL033392, from Williams, S. (month "first seen at NCBI" November 1998), with sequence revision history and disclaimer.			
	IC	NCBI Entrez, Genbank Report, Accession No. AI289177, from NCI-CGAP (month "first seen at NCBI" December 1998), with sequence revision history and disclaimer.			
	ID	NCBI Entrez, Genbank Report, Accession No. AI302167, from NCI-CGAP (month "first seen at NCBI" December 1998), with sequence revision history and disclaimer.			
	IE	NCBI Entrez, Genbank Report, Accession No. AI342264, from NCI-CGAP (month "first seen at NCBI" December 1998), with sequence revision history and disclaimer.			
	IF	NCBI Entrez, Genbank Report, Accession No. AC006088, from Muzny, D. <i>et al.</i> (month "first seen at NCBI" December 1998), with sequence revision history and disclaimer.			
	IG	NCBI Entrez, Genbank Report, Accession No. AI283206, from NCI-CGAP (month "first seen at NCBI" January 1999), with sequence revision history and disclaimer.			
	IH	NCBI Entrez, Genbank Report, Accession No. AI347041, from NCI-CGAP (month "first seen at NCBI" February 1999), with sequence revision history and disclaimer.			
	II	NCBI Entrez, Genbank Report, Accession No. AI312598, from NCI-CGAP (month "first seen at NCBI" February 1999), with sequence revision history and disclaimer.			
	IJ	New England Biolabs Catalog, 199/31994, p. 110 (1993).			
	IK	Kuby et al., 1994, Immunology, second edition, pages 85-96.			
	IL	Abaza et al., J. or Protein Chemistry 11(5):433-444, 1992.			
	IM	Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz, et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.			
	IN	Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Jan 2000, Trends in Biotech. 18(1):34-39.			
	IO	Attwood et al, The babel of bioinformatics, Oct. 2000, Science 290(5491):471-473.			
	IP	Mikayma et al., Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor, Nov. 1993, Proc. Natl. Acad. Sci., USA Vol. 90: 10056-10060.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.